{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:12:31Z","timestamp":1790759551193,"version":"4.1.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Intensive Medicine"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jointm.2022.12.001","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T19:36:32Z","timestamp":1674156992000},"page":"114-123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["The medical treatment of cardiogenic shock"],"prefix":"10.1016","volume":"3","author":[{"given":"Mickael","family":"Lescroart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3565-1818","authenticated-orcid":false,"given":"Benjamin","family":"Pequignot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dany","family":"Janah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7630-2908","authenticated-orcid":false,"given":"Bruno","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jointm.2022.12.001_bib0001","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/HCO.0000000000000957","article-title":"The landscape of cardiogenic shock: epidemiology and current definitions","volume":"37","author":"Palacios Ordonez","year":"2022","journal-title":"Curr Opin Cardiol"},{"issue":"1","key":"10.1016\/j.jointm.2022.12.001_bib0002","first-page":"52","article-title":"Experts' recommendations for the management of adult patients with cardiogenic shock","volume":"5","author":"Levy","year":"2015","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.jointm.2022.12.001_bib0003","doi-asserted-by":"crossref","first-page":"l223","DOI":"10.1136\/bmj.l223","article-title":"Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017: population based cohort study","volume":"364","author":"Taylor","year":"2019","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.jointm.2022.12.001_bib0004","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/ejhf.1922","article-title":"Epidemiology, pathophysiology and contemporary management of cardiogenic shock \u2013 a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"22","author":"Chioncel","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"44","key":"10.1016\/j.jointm.2022.12.001_bib0005","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1093\/eurheartj\/ehy600","article-title":"Treatments targeting inotropy","volume":"40","author":"Maack","year":"2019","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.jointm.2022.12.001_bib0006","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1152\/physrev.1955.35.1.123","article-title":"Determination of cardiac output by equating venous return curves with cardiac response curves","volume":"35","author":"Guyton","year":"1955","journal-title":"Physiol Rev"},{"issue":"2","key":"10.1016\/j.jointm.2022.12.001_bib0007","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF02584229","article-title":"Ventricular interaction with the loading system","volume":"12","author":"Sunagawa","year":"1984","journal-title":"Ann Biomed Eng"},{"issue":"2","key":"10.1016\/j.jointm.2022.12.001_bib0008","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s11517-008-0359-2","article-title":"The arterial Windkessel","volume":"47","author":"Westerhof","year":"2009","journal-title":"Med Biol Eng Comput"},{"issue":"7","key":"10.1016\/j.jointm.2022.12.001_bib0009","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1097\/00003246-199907000-00018","article-title":"Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function","volume":"27","author":"Cain","year":"1999","journal-title":"Crit Care Med"},{"issue":"5","key":"10.1016\/j.jointm.2022.12.001_bib0010","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/ejhf.260","article-title":"Clinical picture and risk prediction of short-term mortality in cardiogenic shock","volume":"17","author":"Harjola","year":"2015","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10.1016\/j.jointm.2022.12.001_bib0011","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.119.005618","article-title":"Epidemiology of shock in contemporary cardiac intensive care units","volume":"12","author":"Berg","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"1","key":"10.1016\/j.jointm.2022.12.001_bib0012","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ehf2.13734","article-title":"Baseline characteristics, management, and predictors of early mortality in cardiogenic shock: insights from the FRENSHOCK registry","volume":"9","author":"Delmas","year":"2022","journal-title":"ESC Heart Fail"},{"issue":"1","key":"10.1016\/j.jointm.2022.12.001_bib0013","first-page":"29","volume":"94","author":"Baran","year":"2019","journal-title":"Catheter Cardiovasc Interv"},{"issue":"9","key":"10.1016\/j.jointm.2022.12.001_bib0014","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJM199908263410901","article-title":"Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock","volume":"341","author":"Hochman","year":"1999","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.jointm.2022.12.001_bib0015","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1208410","article-title":"Intraaortic balloon support for myocardial infarction with cardiogenic shock","volume":"367","author":"Thiele","year":"2012","journal-title":"N Engl J Med"},{"issue":"36","key":"10.1016\/j.jointm.2022.12.001_bib0016","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.jointm.2022.12.001_bib0017","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1161\/01.RES.36.1.185","article-title":"Development of a new catecholamine to selectively increase cardiac contractility","volume":"36","author":"Tuttle","year":"1975","journal-title":"Circ Res"},{"issue":"7877","key":"10.1016\/j.jointm.2022.12.001_bib0018","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0140-6736(74)91754-1","article-title":"Clinical cardiovascular pharmacology of dobutamine. A selective inotropic catecholamine","volume":"2","author":"Jewitt","year":"1974","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jointm.2022.12.001_bib0019","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13613-021-00806-8","article-title":"Current use of inotropes in circulatory shock","volume":"11","author":"Scheeren","year":"2021","journal-title":"Ann Intensive Care"},{"issue":"2","key":"10.1016\/j.jointm.2022.12.001_bib0020","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/0002-9343(80)90387-3","article-title":"Tolerance to dobutamine after a 72\u00a0hour continuous infusion","volume":"69","author":"Unverferth","year":"1980","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.jointm.2022.12.001_bib0021","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.pharmthera.2007.01.008","article-title":"Levosimendan: beyond its simple inotropic effect in heart failure","volume":"114","author":"Antoniades","year":"2007","journal-title":"Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.jointm.2022.12.001_bib0022","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2165\/00003088-200746070-00001","article-title":"Clinical pharmacology of levosimendan","volume":"46","author":"Antila","year":"2007","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.jointm.2022.12.001_bib0023","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/sj.bjp.0706781","article-title":"The levosimendan metabolite OR-1896 elicits vasodilation by activating the K(ATP) and BK(Ca) channels in rat isolated arterioles","volume":"148","author":"Erdei","year":"2006","journal-title":"Br J Pharmacol"},{"issue":"18","key":"10.1016\/j.jointm.2022.12.001_bib0024","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1053\/euhj.2001.3158","article-title":"Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN)","volume":"23","author":"Moiseyev","year":"2002","journal-title":"Eur Heart J"},{"issue":"9328","key":"10.1016\/j.jointm.2022.12.001_bib0025","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0140-6736(02)09455-2","article-title":"Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial","volume":"360","author":"Follath","year":"2002","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.jointm.2022.12.001_bib0026","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1001\/jama.297.17.1883","article-title":"Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial","volume":"297","author":"Mebazaa","year":"2007","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jointm.2022.12.001_bib0027","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jchf.2012.12.004","article-title":"Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure","volume":"1","author":"Packer","year":"2013","journal-title":"JACC Heart Fail"},{"issue":"21","key":"10.1016\/j.jointm.2022.12.001_bib0028","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa1616325","article-title":"Levosimendan for hemodynamic support after cardiac surgery","volume":"376","author":"Landoni","year":"2017","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.jointm.2022.12.001_bib0029","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1616218","article-title":"Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery","volume":"376","author":"Mehta","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jointm.2022.12.001_bib0030","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1016\/j.transproceed.2007.08.077","article-title":"Use of sildenafil in heart transplant recipients with pulmonary hypertension may prevent right heart failure","volume":"39","author":"Maruszewski","year":"2007","journal-title":"Transplant Proc"},{"issue":"2","key":"10.1016\/j.jointm.2022.12.001_bib0031","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/MAT.0000000000000188","article-title":"Outcomes of patients with right ventricular failure on milrinone after left ventricular assist device implantation","volume":"61","author":"Tsiouris","year":"2015","journal-title":"ASAIO J"},{"issue":"14","key":"10.1016\/j.jointm.2022.12.001_bib0032","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017585","article-title":"Phosphodiesterase-5 inhibitor therapy for left ventricular assist device patients: more data, more questions","volume":"9","author":"Gulati","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"10.1016\/j.jointm.2022.12.001_bib0033","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0002-9629(15)41723-9","article-title":"Milrinone: basic and clinical pharmacology and acute and chronic management","volume":"311","author":"Shipley","year":"1996","journal-title":"Am J Med Sci"},{"issue":"6","key":"10.1016\/j.jointm.2022.12.001_bib0034","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1056\/NEJMoa2026845","article-title":"Milrinone as compared with dobutamine in the treatment of cardiogenic shock","volume":"385","author":"Mathew","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.jointm.2022.12.001_bib0035","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1001\/jama.2013.282190","article-title":"Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial","volume":"310","author":"Chen","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jointm.2022.12.001_bib0036","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ijcard.2013.12.276","article-title":"Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: the dopamine in acute decompensated heart failure II (DAD-HF II) trial","volume":"172","author":"Triposkiadis","year":"2014","journal-title":"Int J Cardiol"},{"issue":"9","key":"10.1016\/j.jointm.2022.12.001_bib0037","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1056\/NEJMoa0907118","article-title":"Comparison of dopamine and norepinephrine in the treatment of shock","volume":"362","author":"De Backer","year":"2010","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jointm.2022.12.001_bib0038","first-page":"411","article-title":"Vasopressor use in cardiogenic shock","volume":"26","author":"Levy","year":"2020","journal-title":"Curr Opin Crit Care"},{"issue":"13\u201314","key":"10.1016\/j.jointm.2022.12.001_bib0039","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s00508-006-0630-1","article-title":"Cardiogenic shock \u2013 an inflammatory disease","volume":"118","author":"Heinz","year":"2006","journal-title":"Wien Klin Wochenschr"},{"issue":"14","key":"10.1016\/j.jointm.2022.12.001_bib0040","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1001\/archinte.165.14.1643","article-title":"Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock","volume":"165","author":"Kohsaka","year":"2005","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.jointm.2022.12.001_bib0041","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/1074248414559838","article-title":"Pharmacotherapy update on the use of vasopressors and inotropes in the intensive care unit","volume":"20","author":"Jentzer","year":"2015","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.jointm.2022.12.001_bib0042","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/CCM.0b013e318265ea64","article-title":"Cardiac output response to norepinephrine in postoperative cardiac surgery patients: interpretation with venous return and cardiac function curves","volume":"41","author":"Maas","year":"2013","journal-title":"Crit Care Med"},{"issue":"4","key":"10.1016\/j.jointm.2022.12.001_bib0043","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1161\/01.CIR.90.4.2157","article-title":"More on paradoxical pressor effects of nonselective beta-blockers","volume":"90","author":"Cleophas","year":"1994","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jointm.2022.12.001_bib0044","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/HCO.0000000000000057","article-title":"Pharmacologic therapies for acute cardiogenic shock","volume":"29","author":"Nativi-Nicolau","year":"2014","journal-title":"Curr Opin Cardiol"},{"issue":"12","key":"10.1016\/j.jointm.2022.12.001_bib0045","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.amjcard.2005.07.076","article-title":"Effect of vasopressin on hemodynamics in patients with refractory cardiogenic shock complicating acute myocardial infarction","volume":"96","author":"Jolly","year":"2005","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.jointm.2022.12.001_bib0046","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/CCM.0b013e3181ffe0eb","article-title":"Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study","volume":"39","author":"Levy","year":"2011","journal-title":"Crit Care Med"},{"issue":"2","key":"10.1016\/j.jointm.2022.12.001_bib0047","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2018.04.051","article-title":"Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction","volume":"72","author":"Levy","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jointm.2022.12.001_bib0048","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00134-018-5222-9","article-title":"Epinephrine and short-term survival in cardiogenic shock: an individual data meta-analysis of 2583 patients","volume":"44","author":"L\u00e9opold","year":"2018","journal-title":"Intensive Care Med"},{"issue":"17","key":"10.1016\/j.jointm.2022.12.001_bib0049","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa1312173","article-title":"High versus low blood-pressure target in patients with septic shock","volume":"370","author":"Asfar","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jointm.2022.12.001_bib0050","doi-asserted-by":"crossref","first-page":"451","DOI":"10.4244\/EIJ-D-20-01296","article-title":"Management of cardiogenic shock","volume":"17","author":"Thiele","year":"2021","journal-title":"EuroIntervention"},{"issue":"10","key":"10.1016\/j.jointm.2022.12.001_bib0051","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1080\/15563650.2020.1752918","article-title":"Treatment for beta-blocker poisoning: a systematic review","volume":"58","author":"Rotella","year":"2020","journal-title":"Clin Toxicol (Phila)"},{"issue":"1","key":"10.1016\/j.jointm.2022.12.001_bib0052","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0735-1097(01)01316-X","article-title":"Transient left ventricular apical ballooning without coronary artery stenosis: a novel heart syndrome mimicking acute myocardial infarction. Angina pectoris-myocardial infarction investigations in Japan","volume":"38","author":"Tsuchihashi","year":"2001","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jointm.2022.12.001_bib0053","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ejhf.424","article-title":"Current state of knowledge on Takotsubo syndrome: a position statement from the Taskforce on Takotsubo syndrome of the Heart Failure Association of the European Society of Cardiology","volume":"18","author":"Lyon","year":"2016","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10.1016\/j.jointm.2022.12.001_bib0054","doi-asserted-by":"crossref","first-page":"610","DOI":"10.5603\/CJ.a2016.0100","article-title":"Levosimendan accelerates recovery in patients with takotsubo cardiomyopathy","volume":"23","author":"Yaman","year":"2016","journal-title":"Cardiol J"},{"issue":"6","key":"10.1016\/j.jointm.2022.12.001_bib0055","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1111\/1755-5922.12047","article-title":"Safety and feasibility of levosimendan administration in takotsubo cardiomyopathy: a case series","volume":"31","author":"Santoro","year":"2013","journal-title":"Cardiovasc Ther"},{"issue":"3","key":"10.1016\/j.jointm.2022.12.001_bib0056","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/bja\/aes586","article-title":"Use of vasopressors in Takotsubo cardiomyopathy: a cautionary tale","volume":"110","author":"Redmond","year":"2013","journal-title":"Br J Anaesth"},{"issue":"3","key":"10.1016\/j.jointm.2022.12.001_bib0057","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/j.ijcard.2012.12.092","article-title":"Novel rat model reveals important roles of \u03b2-adrenoreceptors in stress-induced cardiomyopathy","volume":"168","author":"Shao","year":"2013","journal-title":"Int J Cardiol"},{"issue":"3","key":"10.1016\/j.jointm.2022.12.001_bib0058","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/j.ijcard.2011.06.037","article-title":"Rescue extracorporeal life support as a bridge to reflection in fulminant stress-induced cardiomyopathy","volume":"154","author":"Donker","year":"2012","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.jointm.2022.12.001_bib0059","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jtcvs.2007.08.068","article-title":"Pheochromocytoma-induced inverted Takotsubo cardiomyopathy: a case of patient resuscitation with extracorporeal life support","volume":"135","author":"Zegdi","year":"2008","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"39","key":"10.1016\/j.jointm.2022.12.001_bib0060","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"PM","year":"2014","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.jointm.2022.12.001_bib0061","first-page":"3","article-title":"Idiopathic hypertrophic subaortic stenosis. I. A description of the disease based upon an analysis of 64 patients","volume":"30","author":"Braunwald","year":"1964","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.jointm.2022.12.001_bib0062","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1093\/eurheartj\/ehl041","article-title":"Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy","volume":"27","author":"Elliott","year":"2006","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.jointm.2022.12.001_bib0063","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/0002-9149(73)90012-X","article-title":"Hypertrophic subaortic stenosis. Clinical and hemodynamic effects of long-term propranolol therapy","volume":"31","author":"Stenson","year":"1973","journal-title":"Am J Cardiol"},{"issue":"8","key":"10.1016\/j.jointm.2022.12.001_bib0064","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2005.01.012","article-title":"Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Sherrid","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jointm.2022.12.001_bib0065","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1161\/01.CIR.26.2.166","article-title":"Studies on digitalis. V. Comparison of the effects of ouabain on left ventricular dynamics in valvular aortic stenosis and hypertrophic subaortic stenosis","volume":"26","author":"Braunwald","year":"1962","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.jointm.2022.12.001_bib0066","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021141","article-title":"Syndrome of reversible cardiogenic shock and left ventricular ballooning in obstructive hypertrophic cardiomyopathy","volume":"10","author":"Sherrid","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"41","key":"10.1016\/j.jointm.2022.12.001_bib0067","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1093\/eurheartj\/ehac494","article-title":"Empagliflozin in acute myocardial infarction: the EMMY trial","volume":"43","author":"von Lewinski","year":"2022","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.jointm.2022.12.001_bib0068","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1161\/CIRCULATIONAHA.120.052926","article-title":"How should we sequence the treatments for heart failure and a reduced ejection fraction?: a redefinition of evidence-based medicine","volume":"143","author":"McMurray","year":"2021","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.jointm.2022.12.001_bib0069","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1001\/jama.297.15.joc70035","article-title":"Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial","volume":"297","author":"Investigators","year":"2007","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.jointm.2022.12.001_bib0070","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S2213-2600(21)00439-2","article-title":"Single-dose of adrecizumab versus placebo in acute cardiogenic shock (ACCOST-HH): an investigator-initiated, randomised, double-blinded, placebo-controlled, multicentre trial","volume":"10","author":"Karakas","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.jointm.2022.12.001_bib0071","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13063-021-05947-6","article-title":"Low-dose corticosteroid therapy for cardiogenic shock in adults (COCCA): study protocol for a randomized controlled trial","volume":"23","author":"Mekontso Dessap","year":"2022","journal-title":"Trials"},{"issue":"18","key":"10.1016\/j.jointm.2022.12.001_bib0072","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1111\/bph.13235","article-title":"The novel cardiac myosin activator omecamtiv mecarbil increases the calcium sensitivity of force production in isolated cardiomyocytes and skeletal muscle fibres of the rat","volume":"172","author":"Nagy","year":"2015","journal-title":"Br J Pharmacol"},{"issue":"4","key":"10.1016\/j.jointm.2022.12.001_bib0073","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1161\/CIRCHEARTFAILURE.114.002152","article-title":"Myosin activator omecamtiv mecarbil increases myocardial oxygen consumption and impairs cardiac efficiency mediated by resting myosin ATPase activity","volume":"8","author":"Bakkehaug","year":"2015","journal-title":"Circ Heart Fail"},{"issue":"2","key":"10.1016\/j.jointm.2022.12.001_bib0074","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMoa2025797","article-title":"Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure","volume":"384","author":"Teerlink","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jointm.2022.12.001_bib0075","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.008970","article-title":"Developments in exercise capacity assessment in heart failure clinical trials and the rationale for the design of METEORIC-HF","volume":"15","author":"Lewis","year":"2022","journal-title":"Circ Heart Fail"},{"issue":"12","key":"10.1016\/j.jointm.2022.12.001_bib0076","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.jacc.2016.01.031","article-title":"Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure: the ATOMIC-AHF study","volume":"67","author":"Teerlink","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jointm.2022.12.001_bib0077","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/ejhf.1600","article-title":"Circulating dipeptidyl peptidase 3 and alteration in haemodynamics in cardiogenic shock: results from the OptimaCC trial","volume":"22","author":"Takagi","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.jointm.2022.12.001_bib0078","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/ejhf.1601","article-title":"Circulating dipeptidyl peptidase 3 is a myocardial depressant factor: dipeptidyl peptidase 3 inhibition rapidly and sustainably improves haemodynamics","volume":"22","author":"Deniau","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10.1016\/j.jointm.2022.12.001_bib0079","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ahj.2009.03.007","volume":"157","author":"Shah","year":"2009","journal-title":"Am Heart J"},{"issue":"10","key":"10.1016\/j.jointm.2022.12.001_bib0080","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/ejhf.2629","article-title":"Safety and efficacy of istaroxime in patients with acute heart failure-related pre-cardiogenic shock \u2013 A multicentre, randomized, double-blind, placebo-controlled, parallel group study (SEISMiC)","volume":"24","author":"Metra","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.jointm.2022.12.001_bib0081","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/s13054-017-1896-6","article-title":"The effect of angiotensin II on blood pressure in patients with circulatory shock: a structured review of the literature","volume":"21","author":"Busse","year":"2017","journal-title":"Crit Care"},{"issue":"5","key":"10.1016\/j.jointm.2022.12.001_bib0082","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1056\/NEJMoa1704154","article-title":"Angiotensin II for the treatment of vasodilatory shock","volume":"377","author":"Khanna","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jointm.2022.12.001_bib0083","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s13054-018-2225-4","article-title":"Angiotensin in ECMO patients with refractory shock","volume":"22","author":"Ostermann","year":"2018","journal-title":"Crit Care"},{"issue":"1","key":"10.1016\/j.jointm.2022.12.001_bib0084","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13054-019-2337-5","article-title":"Angiotensin II in ECMO patients: a word of caution","volume":"23","author":"Antonucci","year":"2019","journal-title":"Crit Care"},{"issue":"4","key":"10.1016\/j.jointm.2022.12.001_bib0085","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/CIRCULATIONAHA.117.032722","article-title":"Mild hypothermia in cardiogenic shock complicating myocardial infarction","volume":"139","author":"Fuernau","year":"2019","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jointm.2022.12.001_bib0086","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1001\/jama.2021.24776","article-title":"Effect of moderate hypothermia vs normothermia on 30-day mortality in patients with cardiogenic shock receiving venoarterial extracorporeal membrane oxygenation: a randomized clinical trial","volume":"327","author":"Levy","year":"2022","journal-title":"JAMA"}],"container-title":["Journal of Intensive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667100X22001219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667100X22001219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T09:03:07Z","timestamp":1763024587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667100X22001219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S2667100X22001219"],"URL":"https:\/\/doi.org\/10.1016\/j.jointm.2022.12.001","relation":{},"ISSN":["2667-100X"],"issn-type":[{"value":"2667-100X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The medical treatment of cardiogenic shock","name":"articletitle","label":"Article Title"},{"value":"Journal of Intensive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jointm.2022.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V. on behalf of Chinese Medical Association.","name":"copyright","label":"Copyright"}]}}